Quest PharmaTech Inc.
QPTFF · OTC
1/31/2025 | 1/31/2024 | 1/31/2023 | 1/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.01 | 0.01 | 0.00 |
| FCF Yield | -16.19% | -10.05% | -3.25% | -1.33% |
| EV / EBITDA | -4.86 | -2.81 | -21.56 | -16.57 |
| Quality | ||||
| ROIC | -3.65% | -5.45% | -3.12% | -0.89% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.28 | 0.11 | 0.01 | 0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -49.49% | 38.27% | -224.80% | 93.31% |
| Safety | ||||
| Net Debt / EBITDA | -0.98 | -0.22 | -0.76 | -0.32 |
| Interest Coverage | -36.08 | -63.64 | -39.71 | -61.93 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |